Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

17 juil. 2026 08h00 HE | Source: SL Science Holding Limited

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

Joint presentation with Taipei Medical University, JY BioMed, and HeXun Biosciences highlighted the power of gamma delta (γδ) T cells in eliminating glioblastoma in preclinical studies. TAIPEI,...
10 juil. 2026 08h00 HE | Source: SL Science Holding Limited

SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma

Taipei, TAIWAN, July 10, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing...
12 juin 2026 14h51 HE | Source: SL Science Holding Limited

SL BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Market

Post-combination company, SL Science Holding Limited, to commence trading on the Nasdaq Stock Market under the ticker symbol “SLBT”Transaction provides strategic capital to advance proprietary Gamma...
14 janv. 2026 08h30 HE | Source: SL Science Holding Limited

SL BIO Ltd. and Horizon Space Acquisition II Corp. Announce Registration Statement Effectiveness and Extraordinary General Meeting Date to Approve Business Combination

TAIPEI, Taiwan & NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SL BIO Ltd. ("SL Bio" or the “Company”), a biomedical company specializing in developing innovative cellular and gene therapies, and...